B2BROKER
25.3.2024 19:16:31 CET | Business Wire | Press release
The crypto market is on an exciting growth journey, with Bitcoin hitting all-time highs and the total crypto market cap exceeding $2.37T. This coincides with the introduction of MiCA regulation, effective June 30, 2024, and followed by another wave on December 30, 2024, aiming to increase credibility and transparency, fostering wider crypto adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325324392/en/
B2Broker releases B2Trader, an industry-leading crypto spot brokerage solution. (Graphic: Business Wire)
With over 20,000 coins and tokens and a user base of over 300 million traders, compared to the FX market's 128 currency pairs and estimated 50 million traders, crypto is emerging as a more appealing trading option. Its expansion is fueled by its broad adaptation across finance, fintech, payments, and other sectors. Introducing innovative business models through technologies like L2 solutions and blockchain protocols.
To meet the booming crypto trading demand, brokerages are actively seeking solutions to enter the market. And in response, B2Broker announces the release of the B2Trader Brokerage Platform (BBP), a crypto spot broker solution designed to help businesses tap into this growing trend and start generating revenue faster than ever!
Who Can Benefit from B2Trader?
B2Trader is a powerful solution for crypto brokers (CFD and Derivatives), OTC brokers, FOREX brokers, multi-asset and multi-market brokers, market makers, liquidity providers, payment systems, and even banks to follow the market trends and enter the fastest-growing industry.
Here’s how each business model is able to utilise BBP:
FOREX Brokers
B2Trader can be an excellent addition to any FX broker. Along with the traditional trading platforms (MT4, MT5, cTrader, etc.) that mainly handle assets like FX, crypto, equity indices, and precious metals for margin trading or in the form of CFDs, you can add B2Trader to offer crypto spot trading exclusively, attract a new segment of crypto traders interested in physical delivery or ownership, and generate revenue through commissions, markups, and effective risk management.
Additionally, BBP offers a solution for regulated FX brokers to separate their digital asset trading under a different license, promoting strategic diversification and maintaining a competitive advantage in today’s market.
Crypto Brokers
Brokers focusing on crypto CFDs, using crypto as collateral, and offering a mix of FX and crypto CFDs can use B2Trader to enhance existing solutions with crypto spot trading.
Given the competitive nature of client retention and acquisition, the absence of crypto spot trading options could lead clients to seek services elsewhere. Thus, integrating B2Trader is a strategic advantage for brokerages, allowing them to adapt to market trends swiftly, offer much-demanded crypto spot trading, and meet client expectations.
Market Makers
Market makers can use B2Trader to access multiple exchanges, consolidate liquidity efficiently, achieve competitive spreads, optimise pricing, and enable smart routing execution across different venues.
Liquidity Providers
Adding cryptocurrencies to your asset offerings greatly boosts your appeal to brokers, hedge funds and professional traders. B2Trader streamlines this process, equipping you with the essential tools to expand your market reach and accelerate your earnings.
EMIs, Payment Systems, and Banks
For EMIs, PSPs, and banks, B2Trader provides a strategic edge by enabling diverse asset management, monitoring, and liquidity pool creation. It allows these entities to add crypto services to their existing operations, net all transactions, offer crypto accounts, and enable instant swaps.
BBP opens unlimited opportunities as your gateway to crypto and its booming trends. With its comprehensive API and a complete set of essential components and modules, B2Trader seamlessly integrates into any business model.
High-Speed, High-Efficiency, High-Tech
B2Trader is designed for the Enterprise scale of brokers to serve modern financial markets. Even in its most basic setup, it handles 3000 trading instruments and processes up to 3000 requests per second. It offers real-time market data, updates every 100 ms and ultra-fast order execution starting from 1 ms. This can be improved further by enhancing cloud resources and computing.
"Today, B2Broker is a leading name in the FinTech industry. We began operating in the FOREX industry in 2014 and have been developing solutions for the crypto industry since 2017. B2Broker has earned multiple awards and recognitions, and our years of experience have allowed us to understand what the market needs exactly.
That's why we created B2Trader. It's our answer to the changing trends in finance. We have poured 18 months of hard work and over $5 million into B2Trader. BBP is built by our dedicated in-house team of 40 engineers, each contributing to a solution that truly meets the demands of today's brokers. In the next 12 months, we are planning to double the team and enhance our offerings even further!"
— Arthur Azizov, CEO and Founder of B2Broker
Cutting-Edge Technology Stack
BBP focuses on reliability, scalability, and security, using the latest tools and protocols. It is hosted on AWS for its dependable infrastructure, reducing hardware risks. It utilises MongoDB and Amazon Redshift for data management and includes TradingView for market insights.
Kubernetes and Docker support scalable deployments, while CloudFlare provides DDoS protection. The FIX protocol boosts B2Trader's efficiency and reliability.
Powerful Integrations
Developed by B2Broker, B2Trader offers powerful integrations. B2Broker offers a comprehensive suite of products, including a trading platform, OMS, pre-trade and post-trade control, liquidity management system, Trading User Interface, CRM, back office, blockchain wallets for processing and collecting coins/tokens, blockchain management system for automatic payouts and settlements, mobile applications, technical documentation, REST and FIX API protocols, advanced White Label options, and much more.
Additionally, integrated with Marksman, a crypto liquidity distribution engine, B2Trader streamlines administration and ensures market updates with the latest data.
With Marksman, crypto brokers swiftly link to top exchanges by inputting API credentials after opening an account. This allows brokers to create diverse liquidity pools from various exchanges, assign specific execution and routing rules, and establish failover protocols for both the pairs and the liquidity pools.
B2Trader is available as a turnkey solution or for integration with any CRM via REST API. Contact the sales team or your account manager, try out the free demo, and launch your crypto spot broker within a week!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325324392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom